Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Endocrinology
•
Bone and Calcium Disorders
Can romosozumab be used for patients who develop osteoporosis secondary to mild autonomous cortisol excess?
Related Questions
How do you manage osteoporosis in patients with anorexia nervosa (who often are young women < 40)?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
What is your approach to managing osteoporosis in patients with end stage kidney disease?
Is it safe to continue administering Prolia per schedule for osteoporosis treatment shortly after a patient has undergone extensive spinal surgery?
Is there any data or advice on using teriparatide after romosozumab for treatment of postmenopausal osteoporosis?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
What is the utility of an oral calcium loading test to differentiate FHH from secondary hyperparathyroidism due to low calcium intake?
Do you discontinue thiazide treatment used for patients with hypercalciuria and osteoporosis if they develop mild hyponatremia as an adverse effect?
Is there any evidence regarding bone density gains/fracture reduction in the setting of treatment with romosozumab after a two year course of teriparatide?
Do you recommend a particular antiresorptive/anabolic agent for patients who are at high risk for fractures but have high risk of osteonecrosis of the jaw?
